Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Nov 14:14:1294912.
doi: 10.3389/fphar.2023.1294912. eCollection 2023.

Editorial: Drug-ability strategies for potential antimycobacterial candidate: opportunities and challenges

Shasank Sekhar Swain  1 , Sunday Oyedemi  2 , Sudhir Kumar Paidesetty  3 , Soumitra Mohanty  4 , Tahziba Hussain  1
Affiliations
Editorial

Editorial: Drug-ability strategies for potential antimycobacterial candidate: opportunities and challenges

Shasank Sekhar Swain et al. Front Pharmacol. .
No abstract available

Keywords: anti-TB drug development; bioinformatics tools; drug development strategies against tuberculosis; medicinal chemistry and drug synthesis; natural product-based drug discovery.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Comment on

  • Editorial on the Research Topic Drug-ability strategies for potential antimycobacterial candidate: opportunities and challenges

References

    1. Acharya B., Acharya A., Gautam S., Ghimire S. P., Mishra G., Parajuli N., et al. (2020). Advances in diagnosis of Tuberculosis: an update into molecular diagnosis of Mycobacterium tuberculosis . Mol. Biol. Rep. 47 (5), 4065–4075. 10.1007/s11033-020-05413-7 - DOI - PubMed
    1. Aleksandrov A., Myllykallio H. (2019). Advances and challenges in drug design against tuberculosis: application of in silico approaches. Expert Opin. Drug Discov. 14 (1), 35–46. 10.1080/17460441.2019.1550482 - DOI - PubMed
    1. Baranyai Z., Soria-Carrera H., Alleva M., Millán-Placer A. C., Lucía A., Martín-Rapún R., et al. (2021). Nanotechnology-based targeted drug delivery: an emerging tool to overcome tuberculosis. Adv. Ther. 4, 1–22. 10.1002/adtp.202000113 - DOI
    1. Dartois V. A., Rubin E. J. (2022). Anti-tuberculosis treatment strategies and drug development: challenges and priorities. Nat. Rev. Microbiol. 20 (11), 685–701. 10.1038/s41579-022-00731-y - DOI - PMC - PubMed
    1. Dong B., He Z., Li Y., Xu X., Wang C., Zeng J. (2022). Improved conventional and new approaches in the diagnosis of tuberculosis. Front. Microbiol. 13, 924410. 10.3389/fmicb.2022.924410 - DOI - PMC - PubMed

Publication types

LinkOut - more resources